NCT07566897Not yet recruitingPhase 1
A Phase I study to evaluate the safety and efficacy of L19IL2 in combination with ruxolitinib in patients with advanced solid tumors.
Source: EU CTIS (euclinicaltrials.eu) · Last updated 5 Aug 2026
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 96 (estimated)
- First submitted
- 8 Aug 2025
- Start date
- 1 May 2026
- Lead sponsor
- Philogen S.p.A.
- Diseases
- Kidney cancer, Pancreatic cancer, Colorectal cancer
- EU CT number
- 2025-522243-17-00
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 96
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study, not your situation.
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Fondazione Policlinico Universitario Agostino Gemelli IRCCS Coordinator of this site? Confirm its status | Rome | Italy | Not yet recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.